Gelteq's Oral Gel Platform Shows 22% Bioavailability Boost for Medicinal Cannabinoids in Preclinical Study
Key Insights
Gelteq's proprietary oral gel platform demonstrated greater than 22% increase in cannabidiol (CBD) bioavailability compared to an FDA-approved oil-based product in preclinical studies.
The gel formulation achieved higher peak exposure despite containing a much lower concentration of CBD, potentially allowing patients to achieve therapeutic effects with reduced doses.
Results could enable faster market entry through Australia's Special Access Scheme, providing a pathway for expedited launch of medicinal cannabis products without full regulatory approval.
Gelteq Limited (search) announced positive preclinical results demonstrating that its proprietary oral gel delivery platform significantly enhances the absorption and bioavailability of medicinal cannabinoids compared to existing FDA-approved products. The Melbourne-based biotechnology company reported that despite having a much lower concentration of cannabidiol (CBD), its gel formulation achieved greater than 22% increase in bioavailability along with higher peak exposure.
Enhanced Bioavailability with Lower Concentrations
The preclinical study results show that Gelteq's oral gel platform enhances the delivery of lipophilic cannabinoid molecules and delivers more efficient uptake in the body. This improved bioavailability means patients may achieve therapeutic effects with lower doses, potentially reducing exposure to unnecessary excipients or cannabinoids.
The findings demonstrate the platform's ability to overcome limitations associated with traditional medicinal cannabis products, which often present challenges including variable dosing, slow onset, inconsistent absorption, unpleasant taste, and inhalation-related risks.
Pathway to Accelerated Market Access
The positive results create a clear pathway for potential expedited market launch of new medicinal cannabis products in Australia via the Special Access Scheme (SAS). This Australian Government program allows authorized healthcare practitioners to prescribe medicinal cannabis products to patients without the products undergoing the full Therapeutic Goods Administration (search) approval process.
The SAS could potentially grant Gelteq's oral gel platform earlier patient access and a faster pathway to market, positioning the company for efficient entry into additional global markets. According to Gelteq, the study's outcome means the company could directly partner with medicinal cannabis companies without the need for additional studies for this product format.
Addressing Patient Care Challenges
The oral gel format enables pre-measured and precise dosing without the use of droppers and eliminates reliance on food timing, enabling treatment consistency and greater convenience. The gel provides a non-invasive alternative to vaping, which is expected to alleviate concerns around respiratory irritation or long-term inhalation safety.
The ease of administration makes the gel well-suited for patient groups that traditionally struggle with oils or capsules, including pediatric, geriatric, and palliative-care populations.
Commercial Opportunities in Growing Market
Gelteq believes the preliminary results could open significant global commercial opportunities in medicinal cannabis, described as one of the fastest-growing therapeutic markets worldwide. Product differentiation in this sector is increasingly driven by delivery innovation, and the company's platform could enable cannabis producers to improve their offerings beyond conventional oils, vapes, or tinctures.
The enhanced absorption capabilities could accelerate potential licensing, white-label manufacturing, and co-development opportunities across a range of cannabinoid-based products, including CBD, THC, balanced ratios, minor cannabinoids, and combination cannabinoid-nutraceutical formulations.
Broader Platform Applications
In complementary preclinical studies announced in December 2025, Gelteq demonstrated that its gel-based platform can enhance oral delivery of oil-soluble and poorly soluble drugs beyond cannabinoids. The results showed a 300% increase in bioavailability across the first hour compared to an existing FDA-approved reference product, with overall absorption improved by more than 20% over 24 hours.
With more than 40% of approved drugs and up to 90% of developmental candidates affected by poor solubility and bioavailability, Gelteq's platform offers a potential solution to address these widespread pharmaceutical development challenges.